Literature DB >> 24033083

Changes of urinary phospholipids in the chronic kidney disease patients.

Wen-Ling Yang1, Qiong Bai, Dan-Dan Li, Ta-La A, Song Wang, Rong-Sheng Zhao, Hong-Gang Nie, Ai-Hua Zhang, Tao Wang, Min-Hua Fan.   

Abstract

OBJECTIVE: To evaluate whether urinary phospholipids could be regarded as biomarkers of chronic kidney disease.
MATERIALS AND METHODS: Thirteen healthy volunteers and 26 consecutive chronic kidney disease patients were included. Urinary phospholipids were quantified by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
RESULTS: Urinary phosphatidylcholines concentrations (PC 16:0/16:0, 16:0/22:3, 16:0/18:1 and 16:0/18:2) were significantly higher both in glomerulonephritis group (all p < 0.001) and in tubulointerstitial injury group (all p < 0.05) than in healthy control group. Meanwhile, sphingomyelin concentrations (SM 18:1/16:0 and 18:1/18:0) in glomerulonephritis group were significantly higher than those in healthy control group (all p < 0.001). Urinary PCs and SMs were positively correlated with proteinuria but negatively correlated with serum albumin. Meanwhile, PCs were positively correlated with serum creatinine.
CONCLUSION: Our work first demonstrated that urinary phospholipids might be biomarkers for the chronic kidney disease patients. Increased urinary phospholipids in chronic kidney disease patients might result from proteinuria, damaged kidney function or proteinuria induced hypoalbuminemia or lipotoxicity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24033083     DOI: 10.3109/1354750X.2013.837100

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  6 in total

1.  DESI-MSI and METASPACE indicates lipid abnormalities and altered mitochondrial membrane components in diabetic renal proximal tubules.

Authors:  Guanshi Zhang; Jialing Zhang; Rachel J DeHoog; Subramaniam Pennathur; Christopher R Anderton; Manjeri A Venkatachalam; Theodore Alexandrov; Livia S Eberlin; Kumar Sharma
Journal:  Metabolomics       Date:  2020-01-10       Impact factor: 4.290

2.  Top-down lipidomics of low density lipoprotein reveal altered lipid profiles in advanced chronic kidney disease.

Authors:  Ana Reis; Alisa Rudnitskaya; Pajaree Chariyavilaskul; Neeraj Dhaun; Vanessa Melville; Jane Goddard; David J Webb; Andrew R Pitt; Corinne M Spickett
Journal:  J Lipid Res       Date:  2014-11-25       Impact factor: 5.922

3.  Urinary Lipidomics: evidence for multiple sources and sexual dimorphism in healthy individuals.

Authors:  J Graessler; C S Mehnert; K-M Schulte; S Bergmann; S Strauss; T D Bornstein; J Licinio; M-L Wong; A L Birkenfeld; S R Bornstein
Journal:  Pharmacogenomics J       Date:  2017-06-13       Impact factor: 3.550

Review 4.  A narrative review of urinary phospholipids: from biochemical aspect towards clinical application.

Authors:  Xin Li; Kenji Nakayama; Takayuki Goto; Shusuke Akamatsu; Takashi Kobayashi; Koji Shimizu; Osamu Ogawa; Takahiro Inoue
Journal:  Transl Androl Urol       Date:  2021-04

5.  Repeated administration of the NSAID meloxicam alters the plasma and urine lipidome.

Authors:  Sol M Rivera-Velez; Liam E Broughton-Neiswanger; Martin Suarez; Pablo Piñeyro; Jinna Navas; Sandy Chen; Julianne Hwang; Nicolas F Villarino
Journal:  Sci Rep       Date:  2019-03-13       Impact factor: 4.379

6.  Lipidomic and Metabolomic Signature of Progression of Chronic Kidney Disease in Patients with Severe Obesity.

Authors:  Borja Lanzon; Marina Martin-Taboada; Victor Castro-Alves; Rocio Vila-Bedmar; Ignacio González de Pablos; Daniel Duberg; Pilar Gomez; Elias Rodriguez; Matej Orešič; Tuulia Hyötyläinen; Enrique Morales; Francisco J Ruperez; Gema Medina-Gomez
Journal:  Metabolites       Date:  2021-12-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.